Live Breaking News & Updates on Bioinvent Collaborate|Page 5

Stay updated with breaking news from Bioinvent collaborate. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

BioInvent International: BioInvent's BI-1206 to Advance into Expansion Stage of Phase 1/2a Study in NHL after a Productive End-of-Phase 1 FDA Meeting

LUND, SWEDEN / ACCESSWIRE / May 3, 2022 / BioInvent International (STO:BINV)BI-1206 moving into expansion phase as plannedData presented so far include early signs of efficacyNext steps to include planning ....

Martin Welschof , Cecilia Hofvander , Bioinvent International , Bioinvent International Ab Nasdaq Stockholm , Invent International , Nasdaq Stockholm , Senior Director Investor ,

BioInvent International: BioInvent Receives Milestone Payment from Bayer/Hope Medicine Licensing Agreement

LUND, SWEDEN / ACCESSWIRE / April 28, 2022 / BioInvent International (STO:BINV)Lund, Sweden - April 28, 2022 - BioInvent International AB ("BioInvent") (Nasdaq Stockholm: BINV), a biotech company focused ....

Cecilia Hofvander , Bioinvent International , Bioinvent International Ab Nasdaq Stockholm , Invent International , Nasdaq Stockholm , Bayer Healthcare , Shanghai Headquartered Hope Medicine , Hope Medicine ,

BioInvent International: Resolutions at BioInvent's Annual General Meeting 2022

LUND, SWEDEN / ACCESSWIRE / April 28, 2022 / BioInvent International (STO:BINV)The Annual General Meeting ("AGM") of BioInvent International AB ("BioInvent") (Nasdaq Stockholm: BINV) resolved to re-elect ....

Thomas Hecht , Linda Bengtsson , Dharminder Chahal , Cecilia Hofvander , Kristoffer Bissessar , Vincent Ossipow , Bernd Seizinger , Leonard Kruimer , Bioinvent International , Bioinvent International Ab Nasdaq Stockholm , Audit Committee , Remuneration Committee , Swedish Companies , Scientific Committee , Annual General Meeting , Nasdaq Stockholm ,

BioInvent International AB: Interim Report January-March 2022

LUND, SE / ACCESSWIRE / April 27, 2022 / BioInvent International (STO:BINV)"The exciting translational data presented on BI-1808 at AACR clearly show why we are so enthusiastic about our ongoing clinical ....

Martin Welschof , Marie Moores , Cecilia Hofvander , Bioinvent International , Bioinvent International Ab Nasdaq Stockholm , Orphan Drug Designation , Chief Operating , Annual Report , Nasdaq Stockholm ,

BioInvent International AB (publ) Year-End Report January 1

LUND, SWEDEN / ACCESSWIRE / February 23, 2022 / BioInvent International (STO:BINV)"The past year was very exciting for BioInvent. Two of our clinical trials provided highly encouraging results in 2021 ....

United Kingdom , Martin Welschof , Marie Moores , Cecilia Hofvander , Bioinvent International , Bioinvent International Ab Nasdaq Stockholm , Nasdaq Stockholm , Mid Cap , Orphan Drug Designation , Chief Operating , Wednesday February , Senior Director Investor ,